Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets

BACKGROUND: Triple negative breast cancer (TNBC) is high-risk due to its rapid drug resistance and recurrence, metastasis, and lack of targeted therapy. So far, no molecularly targeted therapeutic agents have been clinically approved for TNBC. It is imperative that we discover new targets for TNBC t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaosheng, Guda, Chittibabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265847/
https://www.ncbi.nlm.nih.gov/pubmed/27472710
http://dx.doi.org/10.1097/MD.0000000000004321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265847/
https://www.ncbi.nlm.nih.gov/pubmed/27472710
http://dx.doi.org/10.1097/MD.0000000000004321

Ejemplares similares